Skip to main content

Advertisement

SpringerLink
Log in

Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

PRL-3 genomic copy number is increased in colorectal cancer (CRC), and PRL-3 expression is closely associated with lymph node and liver metastasis of CRC. However, the clinical significance of PRL-3 genomic gain for CRC remains obscure. Here, PRL-3 genomic status in 109 primary CRC tumors and in 44 CRC tumors that had metastasized to the liver, was quantified using real time PCR. Association of PRL-3 genomic status with clinicopathological factors and prognosis was assessed in detail. PRL-3 genomic gain was identified in 31 primary CRC (27.4 %) and was more frequently seen in stage III than in stage II (p = 0.025). Among the clinicopathological factors assessed, PRL-3 genomic gain was significantly associated with poorly differentiated histology (p = 0.0039). Moreover, CRC patients with PRL-3 genomic gain exhibited poorer prognosis than those with no gain in stage II–IV CRC (p = 0.017). PRL-3 genomic gain was identified in 18 (41 %) of the liver metastasis tumors, and this frequency of gain was significantly increased as compared to that of the corresponding primary CRCs (11 %) (p = 0.001). Our findings suggested that PRL-3 genomic gain may represent an aggressive phenotype of primary CRC, and may associate with liver metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. International Agency for Research on Cancer WHO: GLOBOCAN2012 (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx

  2. de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4:769–780

    Article  PubMed  Google Scholar 

  3. Roberts MC, Millikan RC, Galanko JA, Martin C, Sandler RS (2003) Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol 98:857–864

    Article  PubMed  Google Scholar 

  4. Otani T, Iwasaki M, Inoue M (2005) IShoichiro Tsugane for the Japan Public Health, Group. C-bPS: body mass index, body height, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan public health center-based prospective study. Cancer Causes Control 16:839–850

    Article  PubMed  Google Scholar 

  5. Katoh H, Yamashita K, Wang G, Sato T, Nakamura T, Watanabe M (2011) Anastomotic leakage contributes to the risk for systemic recurrence in stage II colorectal cancer. J Gastrointest Surg 15:120–129

    Article  PubMed  Google Scholar 

  6. Katoh H, Yamashita K, Wang G, Sato T, Nakamura T, Watanabe M (2011) Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer. Ann Surg Oncol 18:2432–2441

    Article  PubMed  Google Scholar 

  7. Yamashita K, Watanabe M (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195–199

    Article  CAS  PubMed  Google Scholar 

  8. Katoh H, Yamashita K, Sato T, Ozawa H, Nakamura T, Watanabe M (2009) Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. Br J Surg 96:769–777

    Article  CAS  PubMed  Google Scholar 

  9. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJPJ, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis JDD, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274

    Article  PubMed  Google Scholar 

  10. Hatate K, Yamashita K, Hirai K, Kumamoto H, Sato T, Ozawa H, Nakamura T, Onozato WKY, Ihara A, Watanabe M (2008) Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9. Oncol Rep 20:737–743

    PubMed  Google Scholar 

  11. Molleví DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, Ramos EFJ, Capella G, Villanueva A (2008) PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer 99:1718–1725

    Article  PubMed Central  PubMed  Google Scholar 

  12. Tamagawa H, Oshima T, Yoshihara K, Watanabe T, Numata M, Yamamoto N, Tuschida KSM, Morinaga S, Akaike M, Masuda M, Imada T (2012) The expression of the phosphatase regenerating liver 3 gene is associated with outcome in patients with colorectal cancer. Hepatogastroenterology 59:2122–2126

    PubMed  Google Scholar 

  13. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294:1343–1346

    Article  CAS  PubMed  Google Scholar 

  14. Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C, Velculescu VEKK, Vogelstein B (2003) PRL-3 expression in metastatic cancers. Clin Cancer Res 9:5607–5615

    CAS  PubMed  Google Scholar 

  15. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10:7318–7328

    Article  CAS  PubMed  Google Scholar 

  16. Liu YQ, Li HX, Lou X, Lei JY (2008) Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma. Arch Pathol Lab Med 132:1307–1312

    CAS  PubMed  Google Scholar 

  17. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M (2010) Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer 127:543–554

    Article  CAS  PubMed  Google Scholar 

  18. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara KYH (2007) High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 450:303–310

    Article  CAS  PubMed  Google Scholar 

  19. Wang Z, He YH, Cai SR, Zhan WH, Li ZR, Zhu BH, Chen CQ, Ma JP, Chen ZX, Li W, Zhang LJ (2008) Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int J Cancer 123:1439–1447

    Article  CAS  PubMed  Google Scholar 

  20. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M (2009) Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep 21:1467–1475

    CAS  PubMed  Google Scholar 

  21. Hu L, Luo H, Wang W, Li H, He T (2013) Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis. PLoS One 8:e76927

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Radke I, Götte M, Kersting C, Mattsson B, Kiesel L, Wülfing P (2006) Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer 95:347–354

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hao RT, Zhang XH, Pan YF, Liu HG, Xiang YQ, Wan L, Wu XL (2010) Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer. J Cancer Res Clin Oncol 136:1349–1357

    Article  CAS  PubMed  Google Scholar 

  24. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ, Manser E, Hong W (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63:2716–2722

    CAS  PubMed  Google Scholar 

  25. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M, Gao X, Xu Q (2004) Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164:2039–2054

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, Reik L, McGady DL, Gillespie PPA, Bian H, Reidhaar-Olson JF, Bliss SA, Olivier AR, Sergi JAFD, Danho W, Ritland S, Fotouhi N, Heimbrook D, Niu H (2008) A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res 68:1162–1169

    Article  CAS  PubMed  Google Scholar 

  27. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Waraya M, Kawamata H, Nishimiya HNK, Watanabe M (2011) Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. BMC Cancer 11:122

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A, Broggini M (2005) PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 11:6835–6839

    Article  CAS  PubMed  Google Scholar 

  29. Vogelstein B, Papadopulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann WWJ, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  31. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu AOY, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) ToGA trial investigators: trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687–697

    Article  CAS  PubMed  Google Scholar 

  32. Alexander RJ, Buxbaum JN, Raicht RF (1986) Oncogene alterations in primary human colon tumors. Gastroenterology 91:1503–1510

    CAS  PubMed  Google Scholar 

  33. Rochlitz CF, Hermann R, de Kant E (1996) Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology 53:448–454

    Article  CAS  PubMed  Google Scholar 

  34. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson AHD, Heerdt BG (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57:1769–1775

    CAS  PubMed  Google Scholar 

  35. Masramon L, Arribas R, Tórtola S, Perucho M, Peinado MA (1998) Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer. Br J Cancer 77:2349–2356

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJSS, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RLGA, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703

    Article  CAS  PubMed  Google Scholar 

  37. Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, Zeng Q, Taylor GS, Wang J (2011) Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. Cancer Res 71:234–244

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, Kaldis P, Giaccia AJ, Attardi LD (2008) The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell 30:303–314

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q (2007) PRL-3 down-regulates PTEN expression and signals through PI3 K to promote epithelial-mesenchymal transition. Cancer Res 67:2922–2926

    Article  CAS  PubMed  Google Scholar 

  40. Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, Reik L, McGady DL, Gillespie PPA, Bian H, Reidhaar-Olson JF, Bliss SA, Olivier AR, Sergi JAFD, Danho W, Ritland S, Fotouhi N, Heimbrook D, Niu H (2008) A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res 68:1162–1169

    Article  CAS  PubMed  Google Scholar 

  41. Lee SK, Han YM, Yun J, Lee CW, Shin DS, Ha YR, Kim J, Koh JS, Hong SH, Han DC, Kwon BM (2012) Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells. Int J Cancer 131:E190–E203

    Article  CAS  PubMed  Google Scholar 

  42. Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, Zeng Q (2013) Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest 123:3459–3471

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F GM, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286

    Article  CAS  PubMed  Google Scholar 

  44. Ålgars A, Lintunen M, Carpén O, Ristamäki R, Sundström J (2011) EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 105:255–262

    Article  PubMed Central  PubMed  Google Scholar 

  45. Chong PS, Zhou J, Cheong LL, Liu SC, Qian J, Guo T, Sze SK, Zeng Q, Chng WJ (2014) LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia. Cancer Res 74(11):3043–3053

    Article  CAS  PubMed  Google Scholar 

  46. Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, Zhang SD, Chng WJ, Hong CW, Mills K, Zeng Q (2013) Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. EMBO Mol Med 5(9):1351–1366

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, Sundararajan S, Roumy S, Olivier JF, Robidoux F, Sladek R, Montpetit A, Campbell P, Bezieau S, O’Shea AM, Zogopoulos G, Cotterchio M, Newcomb P, McLaughlin J, Younghusband B, Green R, Green J, Porteous ME, Campbell H, Blanche H, Sahbatou M, Tubacher E, Bonaiti-Pellié C, Buecher B, Riboli E, Kury S, Chanock SJ, Potter J, Thomas G, Gallinger S, Hudson TJ, Dunlop MG (2007) Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39(8):989–994

    Article  CAS  PubMed  Google Scholar 

  48. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, CORGI Consortium, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39(8):984–988

    Article  CAS  PubMed  Google Scholar 

  49. Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, Shin A, Jee SH, Kim DH, Cai Q, Long J, Shi J, Wen W, Yang G, Zhang Y, Li C, Li B, Guo Y, Ren Z, Ji BT, Pan ZZ, Takahashi A, Shin MH, Matsuda F, Gao YT, Oh JH, Kim S, Ahn YO, Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Chan AT, Chang-Claude J, Slattery ML, Colorectal Transdisciplinary (CORECT) Study, Gruber SB, Schumacher FR, Stenzel SL, Colon Cancer Family Registry (CCFR), Casey G, Kim HR, Jeong JY, Park JW, Li HL, Hosono S, Cho SH, Kubo M, Shu XO, Zeng YX, Zheng W (2014) Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Nat Genet 46(6):533–542

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41(8):882–884

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti MA, Bilchik AJ, Van Cutsem EJ, Chiang JM, D’Angelica MI (2008) Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 26(29):4828–4833

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kitasato University School of Medicine, Asamizodai 2-1-1, Minami-ku, Sagamihara, Kanagawa, 252-0380, Japan

    N. Nakayama, K. Yamashita, T. Tanaka, H. Kawamata, A. Ooki, T. Sato, T. Nakamura & M. Watanabe

Authors
  1. N. Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kawamata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Ooki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Yamashita.

Ethics declarations

Conflict of interest

There is no conflict of interest in the current study.

Ethical statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Kitasato University School of Medicine. Informed consent was obtained before surgery.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakayama, N., Yamashita, K., Tanaka, T. et al. Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis. Clin Exp Metastasis 33, 3–13 (2016). https://doi.org/10.1007/s10585-015-9749-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-015-9749-7

Keywords

Search

Navigation